1 / 5

Pharmaceutical Fine Chemicals Market Analysis and Future

As stated by a report by P&S Intelligence, the global pharmaceutical fine chemicals market attained a revenue of $100.3 billion in 2019 and is predicted to progress at a 6.2% CAGR during the forecast period (2020u20132030). The key driving factors of the market are the growing geriatric population and the rising manufacturing of medical drugs in Asia-Pacific (APAC). When drug type is taken into consideration, the market is bifurcated into non-proprietary and proprietary, between which, the latter bifurcation held the major share of the market in 2019.

psmarket
Download Presentation

Pharmaceutical Fine Chemicals Market Analysis and Future

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceutical Fine Chemicals Market To Grow at 6.2% CAGR between 2020 and 2030 1 ©P&SIntelligence.Allrightsreserved

  2. Factors such as the rise in the elderly population and the rapid growth in the pharmaceutical industry in the APAC region will help the pharmaceutical fine chemicals market to grow at a CAGR of 6.2% between 2020 and 2030. In contemporary years, the surging focus of African countries, such as Nigeria and Kenya, on local production of medical drugs and improvement of public health is creating huge growth opportunities for key market players. The booming geriatric population will drive the demand for pharmaceutical fine chemicals, worldwide, as the weak immunity of old people makes them vulnerable to numerous diseases. For instance, the global population of individuals aged 65 years and more surged from 699,061,108 in 2019 to 723,184,486 in 2020, as per the World Bank. Furthermore, the WHO predicts that 1 in 6 people in the world will be aged 60 years or above by 2030. In addition, the UNDESA forecasts that the population of people aged 65 years or over will reach around 1.5 billion by 2050. Request for sample pages of this report: https://www.psmarketresearch.com/market- analysis/pharmaceuticals-fine-chemicals-market/report-sample In 2019, the proprietary category, within the drug type segment, accounted for a larger share in the pharmaceutical fine chemicals industry, owing to the extensive R&D efforts being made in drug development. The development of proprietary drugs requires massive capital investment and adequate quality control measures. Pharmaceutical companies are mandated to ensure the integrity of ingredients of such drugs to make the final product safe and effective, owing to the toughening regulations on drug development and discovery. Presently, players of the pharmaceutical fine chemicals industry are engaging in partnerships and joint ventures to accelerate their growth. For instance, in December 2018, GE Healthcare agreed to provide a biologics production plant to Lonza Group Ltd. in Guangzhou, China. With this agreement, Lonza Group aimed to fulfill the burgeoning demand for contract manufacturing and developing services in China. Other companies opting for such strategic measures include AlzChem Group AG, Albany Molecular Research Inc., BASF SE, and Clariant AG. According to P&S Intelligence, the North American pharmaceutical fine chemicals market generated the highest revenue in the years gone by, owing to the presence of the world's largest pharmaceutical industry in the region. This region is home to several key market players, such as Pfizer Inc., Johnson & Johnson, and Abbott Laboratories, which are increasingly focusing on R&D activities to develop medication for untreatable diseases. Additionally, the high healthcare expenditure in regional countries is also a key contributor to the market growth in North America. Browse full report at: https://www.psmarketresearch.com/market- analysis/pharmaceuticals-fine-chemicals-market

  3. Whereas, the APAC pharmaceutical fine chemicals market is expected to showcase the fastest growth during this decade, owing to the soaring R&D investments in the pharmaceutical sector and the booming geriatric population, especially in India and China. According to the UN ESCAP, the number of people aged more than 65 years in India and China was 90,720,000 and 172,262,000, respectively, in 2020. As per the UNFPA, 1 in 4 people in the APAC region will be over 60 years of age by 2050. Thus, the growing elderly population and the booming pharmaceutical sector in APAC countries will fuel the demand for pharmaceutical fine chemicals, globally. Market Size Breakdown by Segment By Drug Type Proprietary Non-Proprietary By Product Basic Building Blocks Advanced Intermediates Active Ingredients By Application Cardiovascular Neurological Oncological Respiratory Gastrointestinal Musculoskeletal Regional Analysis North America • • • • • • • • • • • • oU.S. oCanada Europe • oU.K. oGermany oItaly oFrance oSpain oBelgium Asia-Pacific • oChina oJapan oIndia oSouth Korea Latin America • oBrazil oMexico

  4. oArgentina Middle East & Africa • oSouth Africa oU.A.E. oSaudi Arabia oTurkey 3 © P&S Intelligence. All rights reserved

  5. Disclaimer: P&S Intelligence always keeps its customers’ interests at the core while carrying out research activities. P&S Intelligence ensures the reliability and accuracy of information and data provided in its market research publications. However, the information in publications is subject to fluctuations, as it is based on primary interviews of officials from various companies or organizations. P&S Intelligence is not responsible for any incorrect data provided by the key industry players of the concerned domain. The information or analysis in P&S Intelligence publications represents opinions based on research and should not be interpreted as statements of fact. Information in this report was believed to be correct at the time of publication, but cannot be guaranteed. P&S Intelligence does not endorse any product, service, or vendor depicted in its research publications. All intellectual properties, including trademarks and copyrights, belong to their respective owners and may be protected by copyright. Under no circumstance can these be reproduced in any form without prior written agreement of their owners. An order for market research report is intended for internal use of the company only and not for disclosure to third parties or any other publication in general. No service, report, or part thereof provided by P&S Intelligence can be reproduced, republished, resold, revealed, distributed, circulated, or sublicensed in any medium or form now realized or hereafter become realized, including but not limited to, all forms of optical-based media, magnetic, electronic, or digital, without a written permission from Prescient & Strategic Intelligence Pvt. Ltd. Kindly write to: enquiry@psmarketresearch.com B-13, Sector – 2, Noida, U.P. – 201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886 4 ©P&SIntelligence.Allrightsreserved

More Related